First-line treatment options in metastatic renal cell cancer

Authors

  • Anil Kapoor

DOI:

https://doi.org/10.5489/cuaj.4307

Abstract

The introduction of targeted therapy a decade ago revolutionized the treatment of metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin (mTOR). Currently recommended first-line treatments in Canada include sunitinib, pazopanib, and temsirolimus. With the heterogeneity of mRCC disease, the choice of treatment is driven largely by prognostic factors.

Downloads

Download data is not yet available.

Downloads

Published

2016-12-15

How to Cite

Kapoor, A. (2016). First-line treatment options in metastatic renal cell cancer. Canadian Urological Association Journal, 10(11-12), S236–8. https://doi.org/10.5489/cuaj.4307